Bionano Genomics, Inc.
BNGO
$3.77
-$0.08-2.08%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -13.36% | -26.37% | -23.86% | -34.83% | -10.29% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -13.36% | -26.37% | -23.86% | -34.83% | -10.29% |
| Cost of Revenue | -37.22% | -40.81% | -42.70% | 121.02% | -18.38% |
| Gross Profit | 34.51% | 4.04% | 40.16% | -407.24% | 12.00% |
| SG&A Expenses | -27.78% | -54.21% | -95.48% | -61.99% | -57.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -38.35% | -57.91% | -76.68% | -36.57% | -50.78% |
| Operating Income | 50.64% | 68.28% | 96.76% | 37.03% | 59.73% |
| Income Before Tax | 57.73% | 90.16% | 54.19% | 60.70% | 58.34% |
| Income Tax Expenses | -61.54% | 138.89% | 102.78% | -38.46% | -21.21% |
| Earnings from Continuing Operations | 57.74% | 90.13% | 54.15% | 60.69% | 58.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 57.74% | 90.13% | 54.15% | 60.69% | 58.31% |
| EBIT | 50.64% | 68.28% | 96.76% | 37.03% | 59.73% |
| EBITDA | 57.94% | 74.69% | 105.38% | 47.46% | 64.44% |
| EPS Basic | 86.17% | 96.78% | 81.52% | 83.98% | 80.56% |
| Normalized Basic EPS | 88.18% | 96.26% | 95.11% | 73.46% | 77.28% |
| EPS Diluted | 86.17% | 96.78% | 81.52% | 83.98% | 80.56% |
| Normalized Diluted EPS | 88.18% | 96.26% | 95.11% | 73.46% | 77.28% |
| Average Basic Shares Outstanding | 205.60% | 206.48% | 148.09% | 145.32% | 114.48% |
| Average Diluted Shares Outstanding | 205.60% | 206.48% | 148.09% | 145.32% | 114.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |